REPL - NASDAQ
Replimune Group, Inc.
$9.98
+13%Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
At a Glance
Live SnapshotNo Dividend Yield Data
REPL has not reported any dividend yield values in the available annual periods.
No Dividend Payout Ratio Data
REPL has not reported any dividend payout ratio values in the available annual periods.
No Net Dividends Paid Data
REPL has not reported any net dividends paid values in the available annual periods.
Replimune Group, Inc. Dividend History
REPL Dividend Payment History
| Declaration | Ex-Date | Payment Date | Dividend | Adjusted | Frequency | Growth |
|---|---|---|---|---|---|---|
| No dividend payment history available | ||||||
Replimune Group, Inc. Payout Ratio Analysis
Dividend Sustainability Analysis
Payout Ratio
Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.
FCF Payout Ratio
Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.
Sustainability
Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.
Related Guides
Continue your REPL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.